Skip to content

Bicara Therapeutics BCAX Operating Lease Liabilities (Total)

Operating Lease Liabilities (Total) at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$5.9M-25.0%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%
Nuvation Bio logo
Nuvation BioNUVB
$4.04M-29.5%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$20.89M+189%
Erasca, Inc. logo
Erasca, Inc.ERAS
$45.95M-9.6%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$18.66M+84.3%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.

The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's operating lease liabilities (total).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's operating lease liabilities (total)?
Bicara Therapeutics (BCAX) reported operating lease liabilities (total) of $1.71M in Q4 2025.
What does operating lease liabilities (total) mean?
This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.